A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. (6th November 2014) - Koch, Sven D; Hong, Henoch; Feyerabend, Susan; Retz, Margitta; Kuebler, Hubert; Heidenreich, Axel; van Erps, Thomas; Schroeder, Andreas; Scheel, Birgit; Reus, Valérie; Kallen, Karl-Josef; Fotin-Mleczek, Mariola; et al.